Why the study?
Heart transplant recipients face potential complications that worsen outcomes, necessitating a practical clinical framework and an update on the relatively unknown complication of eosinophilic myocarditis.
This review provides a practical framework for managing heart transplant recipients, with a specific focus on rejection and the rare complication of eosinophilic myocarditis.
Heightens vigilance for eosinophilic myocarditis in heart transplant recipients; extends rejection management frameworks in advanced HF but should not yet change practice.
Many patients with heart failure (HF) progress to an advanced stage, characterized by persistent symptoms despite maximal therapy. Heart transplantation (HT) remains the most effective treatment option for improving the survival of patients with advanced HF. This is true even with advancements in medical therapy for HF and the development of mechanical circulatory support systems. Over the past few decades, HT has undergone significant evolution, leading to greatly improved success rates. However, HT recipients face the risk of several potential complications that can negatively impact their outcomes. In this article, we aim to provide a practical framework for clinicians involved in heart transplant medicine. Additionally, we offer an update on a recent and relatively unknown complication of HT: eosinophilic myocarditis (EM).
No takes yet. Share an insight, caveat, or question.
Panebianco et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: